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Abstract 
 
Purpose of review: Immunotherapy is an emerging treatment strategy against various 
cancer types including glioblastoma. It comprises different strategies to induce, boost or 
restore an anti-tumor immune response. This review provides an overview of recent pre-
clinical and clinical developments in the field of immunotherapy against glioblastoma. We 
elucidate the concepts and challenges and point out the strengths and weaknesses of the 
most promising immunotherapeutic approaches.  
 
Recent findings: Immunotherapy is one of the most active research areas in glioblastoma. 
Data from pre-clinical work as well as phase I and phase II clinical trials revealed that 
immunotherapy against glioblastoma is overall safe and able to promote a potent anti-tumor 
immune response. Among the therapeutic approaches which are currently under 
investigation, vaccination, e.g. against EGFRvIII, as well as immune checkpoint inhibition 
targeting receptors such as CTLA-4 and PD-1, are among the most promising and advanced 
treatment strategies. However, there are considerable challenges to overcome such as the 
identification of novel target molecules for vaccination, appropriate patient selection 
criteria, strategies to prevent or handle immune-related adverse events and the 
implementation of immunotherapy in multimodal treatment regimens together with 
conventional treatment strategies.  
 
Summary: Key features of immunotherapy are target specificity, adaptability and durability. 
Results from preclinical assessments and clinical trials applying immunotherapy alone or in 
combination with conventional treatment options are promising. However, intense research 
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and stringent clinical development are required to optimize the available treatment options 
and to overcome potential pitfalls.  
 
Keywords: Glioma, brain tumor, vaccination, checkpoint inhibition, PD-1, nivolumab, 
pembrolizumab 
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Introduction 
Glioblastoma is the most common primary malignant brain tumor in adults. Despite multi-
modal treatment approaches including surgery, radiotherapy and chemotherapy, the 
median survival is limited to approximately 16 months within clinical trial populations (1). 
Accordingly, novel treatment modalities are urgently required. One of these is cancer 
immunotherapy. The recent advances achieved with immunotherapy in the treatment of 
patients affected by melanoma (2, 3) and other tumor entities sparked widespread interest 
in the field and stimulated research exploring different immunotherapeutic strategies also 
against glioblastoma. In contrast to other tumors, glioblastoma is considered poorly 
immunogenic and its localization in the brain may further impede powerful immune 
responses. Glioblastoma is characterized by defects in host cell-mediated immunity as well 
as various tumor-derived immune-inhibitory signals which confer an immunosuppressive 
microenvironment (4, 5). However, the emergence of advanced immunotherapeutic 
approaches may now allow for an efficient targeting of glioblastoma by immunotherapy. The 
available concepts (Fig. 1) can be categorized by their dependence on the host immune 
system and their antigen specificity (6) despite many intersections resulting from the 
enormous complexity of the immune system. Within this review article, we illustrate the 
basic principles underlying the different immunotherapeutic strategies, their strengths and 
weaknesses and applications in the context of glioblastoma. 
 
Peptide vaccination 
This approach pursues an antigen-specific anti-tumor immune response by vaccination with 
full-length tumor antigens or short antigenic peptide fragments that are administered 
intramuscularly, subcutaneously or intradermally together with adjuvants. One of the best 
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studied single-target approaches used for vaccination against glioblastoma is the variant III 
of the epidermal growth factor receptor (EGFRvIII). This mutated EGFR variant results from 
an in-frame deletion of exons 2-7 of the gene. It owns many features of an ideal 
immunotherapeutic target which are cell surface expression, tumor-tissue specificity 
including expression on cancer stem cells and an association with tumor-driving mechanism 
(7, 8). Rindopepimut (Rintega®), a clinically advanced peptide vaccine targeting EGFRvIII, is a 
14-mer peptide conjugated to keyhole limpet hemocyanin (KLH) that is administered 
intradermally together with granulocyte-macrophage colony-stimulating factor (GM-CSF). 
Rindopepimut has been assessed within several clinical trials so far. The so far largest phase 
II clinical trial, ACT III (9), demonstrated good tolerability except for grade 1/2 injection side 
reactions when rindopepimut was administered together with maintenance temozolomide 
therapy in patients with newly diagnosed glioblastoma. This trial demonstrated a robust, 
specific and durable immune response as well as encouraging PFS and OS compared to 
historical controls and confirmed previous results obtained with rindopepimut in 
glioblastoma patients (10, 11). Anti-EGFRvIII antibody titers may be potentially useful to 
monitor the immune response mediated by rindopepimut. An international multicenter, 
phase III randomized trial assessing the efficacy of rindopepimut in patients with newly 
diagnosed EGFRvIII-positive glioblastoma has completed accrual and the results need to be 
awaited (ACT IV; NCT01480479). Furthermore, rindopepimut has been assessed in a 
randomized phase II study in patients with recurrent glioblastoma. Here, the vaccine was 
used in combination with bevacizumab and compared to bevacizumab in combination with 
placebo injection. Again, anti-EGFRvIII immune responses were induced and the median OS 
was 11.6 months in the rindopepimut arm compared to 9.3 months in the placebo group 
(p=0.0386; HR 0.57 for the intention-to-treat (ITT) population) (12). Limitations of EGFRvIII-
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based vaccination include the presence of EGFRvIII on only 20-30% of all glioblastomas as 
well as potential antigen-loss in recurrent tumors following vaccination.  
While rindopepimut targets a naturally occurring neoepitope, Hashimoto and colleagues 
performed a phase I study using a modified HLA-A*2402-restricted 9-mer peptide of the 
Wilms tumor peptide 1 (WT-1) in which an amino acid at the MHC anchor position was 
replaced to increase binding affinity to the MHC molecule. Intradermal vaccination of the 
peptide emulsified in Montanide ISA51 in combination to temozolomide chemotherapy 
resulted in only minor toxicity in patients with newly diagnosed glioblastoma (13). This 
modified peptide induced mainly a cellular immune response. 
Another promising target for peptide vaccination is a neoepitope derived from isocitrate 
dehydrogenase (IDH)-1, a key metabolic enzyme in the tricarboxylic acid cycle. The most 
common IDH-1 mutation, that is R132H, is found in the majority of low-grade and anaplastic 
gliomas as well as secondary glioblastomas. This mutation contains an immunogenic epitope 
suitable for mutation-specific vaccination in the context of MHC class II. Vaccination with a 
peptide containing the IDH-1 R132H mutation induced a mutation-specific CD4 T cell and 
antibody response in humanized mice and reduced the growth of subcutaneous mouse 
sarcoma cells that were engineered to express the IDH1 R132H mutation (14). So far, it 
remains unknown whether this vaccine is also active in orthotopic brain tumor models. 
Several clinical studies using an IDH-1-specific peptide vaccine are currently being planned to 
assess this approach in patients with IDH-1 mutant recurrent grade II glioma such as the 
RESIST (NCT02193347) trial and in patients affected by IDH1-mutant grade III or IV gliomas 
such as the NOA-16 trial (EudraCT no. 2014-000503-27).  
In addition to vaccination approaches that use single peptides as immunogens, there are 
also concepts which rely on multi-peptide vaccination. Such multi-peptide strategies may 
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potentially be more effective in boosting immune responses. Two phase I studies 
demonstrated the safety and immunogenicity of subcutaneous vaccinations with a cocktail 
of synthetic peptides derived from HLA-A2 restricted glioma-associated antigens of ephrin 
type-A receptor 2 (Epha2), interleukin-13 receptor subunit alpha-2 (IL-13Rα), survivin and 
WT-1. Within the first study, children with brain stem or high-grade gliomas were enrolled 
and treated with the vaccine in combination with radiotherapy or chemoradiotherapy (15). 
In the second study, vaccination with the multi-peptide formulation was applied to adults 
with high-risk diffuse cerebral gliomas (16). In both trials, a combination of potent adjuvants 
was administered, i.e. pan-HLA-DR tetanus toxoid peptide (TetA830) to enhance CD4 T 
helper cell responses and polyICLC to promote type I polarization of T cell responses and 
Montanide-ISA-51 which promotes antigen-specific cytotoxic T cells. The application of this 
multi-peptide mixture led to antigen-specific T cell responses as quantified by interferon 
(IFN)-y Enzyme-Linked ImmunoSpot (ELISPOT) assays. Another multi-peptide formulation 
currently being tested is IMA-950 (NCT01920191). It contains 11 HLA-binding tumor-
associated antigens (TAA) and is administered in combination with GM-CSF and imiquimod 
following a single dose of cyclophosphamide. The latter is supposed to deplete regulatory T 
cells which may interfere with a potent anti-tumor immune response. Two of the epitopes 
are CD4 T cell epitopes following the principle to recruit both CD4 and CD8 T cells. 
Fundamental challenges specific for peptide vaccinations are the identification of 
appropriate target antigens as well as immune escape of the tumor resulting from antigen 
loss following treatment.  
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Dendritic cell (DC)-based therapy 
These approaches use DC to prime a tumor-specific immune response. DC are professional 
antigen-presenting cells, placed at the interface between the innate and the adaptive 
immune system, orchestrating various immunological functions including humoral as well as 
cellular immune responses. This treatment usually requires the isolation of patient- or 
donor-derived monocytes, followed by ex vivo amplification, maturation and subsequent 
exposure to a source of tumor-antigens, e.g. autologous tumor lysate or tumor-antigen-
derived peptides.  Alternatively, DC can be pulsed with mRNA derived from the tumor bulk 
or specifically encoding for tumor-antigens. Challenges specific to these approaches are the 
differences of the antigen-processing machinery of DC and tumor cells (17). As a 
consequence, the MHC-binding epitopes of tumor antigens presented by DC and the ones 
that are presented in the context of MHC on tumor cells may vary. Furthermore, there is the 
potential risk of peripheral tolerance induction due to inadequate dendritic cell maturation 
signals. Adjuvants such as GM-CSF and IL-4 are frequently added to DC-based vaccines, also 
in glioblastoma trials (18). Various DC-based vaccination concepts have been examined 
within the last years, mostly within small, uncontrolled trials (19, 20). Accordingly, the anti-
glioma activity of DC-based approaches has remained largely unclear. A clinically advanced 
concept of DC-based therapy is vaccination with ICT-107, an autologous vaccine of patient-
derived DC pulsed with six synthetic, glioma-associated MHC class I peptides derived from 
absent in melanoma 2 protein (AIM-2),  melanoma-associated antigen 1 (MAGE1), tyrosinase 
related protein-2 (TRP-2),  glycoprotein 100 (gp100), human epidermal growth factor 
receptor 2 (HER2/neu), and IL-13Rα2. Treatment with ICT-107 was safe and immunogenic in 
a phase I trial (21) and resulted in promising survival times in a phase II trial in patients with 
newly diagnosed glioblastoma. The effect was particularly encouraging in HLA-A2-positive 
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patients (22). DCVax®-L is another DC-based vaccine which is generated using autologous DC 
pulsed with autologous tumor cell lysate. Despite the lack of compelling data from phase I or 
II studies, the vaccine is currently being assessed in a phase III trial in patients with newly 
diagnosed glioblastoma (NCT00045968). 
A recent phase I clinical trial assessed a novel strategy to improve the efficacy of DC-based 
vaccination. Within this study, a vaccine site pre-conditioning strategy was applied by 
inducing inflammation at the vaccine site with tetanus/diphtheria (Td) toxoid prior to 
vaccination with CMV-specific DC pulsed with pp65 RNA (23). This approach resulted in a 
significant increase in PFS and OS in patients with newly diagnosed glioblastoma compared 
to subjects treated with DC alone.  
 
Adoptive cell therapy 
This strategy is a cell-based anti-tumor immunotherapy which involves the collection of 
circulating or tumor-infiltrating lymphocytes, their ex vivo expansion, activation, e.g. with 
cytokines and/or potential tumor antigens, and/or genetic modification as well as their re-
administration to patients.  
In a preclinical model, alloreactive cytotoxic T cells, derived from an HLA-disparate donor 
animal, were active against experimental gliomas (24). The intratumoral injection of 
alloreactive T cells is currently assessed in a phase I study (NCT01144247) in patients with 
recurrent malignant gliomas or meningiomas. A more specific strategy is the development 
and application of T cells with genetically modified antigen-recognizing receptors. These 
chimeric antigen receptors (CAR) are based on a transmembrane protein which comprises 
the tumor-antigen binding domain of an immunoglobuline linked to one or more 
immunostimulatory domains. This approach has the advantage that it works independently 
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of the available T cell repertoire of a patient, which has undergone selection in the thymus 
to maintain central tolerance. Furthermore, it circumvents the drawbacks of classical MHC 
restriction, i.e. the need for antigen processing and presentation. Similar to other antigen-
specific strategies, CAR-based therapies require the identification of appropriate target 
antigens which are expressed in a tumor-specific manner. Only such antigens may allow for 
specific targeting as well as potent anti-tumor effects in the absence of off-target immune-
related cytotoxicity. Furthermore, most available CAR only target a single epitope which 
renders this strategy vulnerable to antigen loss. In addition, many protocols for isolation and 
expansion of T cells for transduction with a transgene encoding for the CAR select 
predominantly CD8 T cells, neglecting potent anti-tumor effects mediated by CD4 T cells 
(25). Furthermore, when murine-based single-chain fragment variable domains are used, 
human anti-mouse antibodies may potentially lead to anaphylactic side effects and 
neutralization of effector cells (26). The most advanced CAR T cell studies against 
glioblastoma use EGFRvIII as their target. Murine and humanized CAR against EGFRvIII 
displayed pronounced anti-glioma activity in preclinical in vitro and in vivo models (27). An 
inherent problem of such preclinical models involving xenogenic implantation of human 
tumor cells and CAR T cells is their inability to predict CAR-mediated auto-immune side 
effects. In the context of EGFRvIII, this point was addressed by another preclinical study that 
tested an EGFRvIII-specific murine CAR in a syngeneic, fully immunocompetent mouse 
glioma model (28). Here, the infusion with EGFRvIII CAR T cells cured all mice harboring 
orthotopic gliomas and induced immunological memory without apparent toxicity.  A 
prerequisite for EGFRvIII CAR T cell activity was the depletion of lymphocytes in the host 
prior to adoptive CAR T cell transfer. Based on the promising results of these preclinical 
studies, a phase I clinical trial (NCT02209376) was initiated assessing T cells transduced with 
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a lentiviral vector to express a human EGFRvIII CAR in patients with EGFRvIII-positive 
glioblastoma.  
Another target for CAR T cell therapy against glioblastoma is IL13Rα2 which is selectively 
expressed in glioblastoma including glioma-initiating cells. The CAR targeting IL13Rα2 are 
based on ligands that are coupled to intracellular signaling elements for T cell stimulation. 
Administration of CAR T cells targeting IL13Rα2 resulted in prolonged survival in an 
orthotopic mouse glioma xenograft model (29). A phase I trial (NCT01109095) assesses the 
safety of cytotoxic T lymphocytes engineered to express a CAR targeting EGFR2 (HER2). HER2 
is expressed by a subset of glioblastomas and may therefore be a suitable target for CAR-
based treatment.   
 
Immune checkpoint inhibitors 
Within the last years, a new class of drugs has emerged which has been called “immune 
checkpoint inhibitors”. These agents block inhibitory immune cell receptors or their 
corresponding ligands with the ultimate goal to reverse peripheral T cell tolerance. 
Established target molecules are cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and 
the receptor programmed cell death-1 (PD-1) as well as its ligand PD-L1. The CTLA-4 blocking 
antibody ipilimumab was the first immune checkpoint inhibitor that obtained approval for 
the treatment of patients with metastatic melanoma (2).  PD-1 blocking drugs such as 
nivolumab or pembrolizumab have shown unprecedented activity in patients with advanced 
melanoma and other tumor entities (30, 31). However, similar to other immunotherapeutic 
approaches, only some of the patients may benefit from treatment with immune checkpoint 
inhibitors.  So far, it remains unclear whether the expression of PD-L1 by tumor cells is 
required for sustained activity of anti-PD-1 antibodies. A further concern is that these 
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molecules do not induce tumor-specific immune responses but may cause off-target effects 
related to a general activation of the immune system. Preclinical data suggest that such 
agents may also work against tumors in the brain (32). Currently, clinical trials assessing the 
activity of immune checkpoint inhibitors in glioblastoma patients are ongoing. A phase III 
study comparing the efficacy of the PD-1 antibody nivolumab with bevacizumab in patients 
with recurrent glioblastoma has completed accrual (NCT02017717). A small safety run-in 
cohort of patients within this trial was treated with nivolumab in combination with 
ipilimumab. Due to considerable toxicity in this combination arm, only single agent 
nivolumab was used in the phase III part of the trial (33). Clinical trials adding PD-1 inhibitors 
or ipilimumab to standard chemoradiotherapy in patients with newly diagnosed gliobastoma 
are currently being planned. 
 
Further immunotherapeutic strategies under development 
Tumor-targeting antibodies 
Beside checkpoint inhibitors, other strategies based on monoclonal antibodies comprise 
drugs acting as agonists for costimulatory immune cell receptors such as 4-1BB or OX40 
aiming at more efficiently activating immune effector cells (34, 35). Immunoconjugates are 
antibodies directed against tumor-associated or tumor-specific antigens which are coupled 
to toxins or radioisotopes which may promote the induction of cell death. A clinically 
advanced antibody conjugate is ABT-414, an antibody recognizing amplified or mutated 
EGFR on tumor cells that is coupled to the toxic anti-microtubule agent 
monomethylauristatin. ABT-414 alone or in combination with temozolomide was assessed in 
a phase I study in patients with recurrent glioblastoma (36). Ocular adverse events were 
common and further studies assessing the anti-tumor activity of ABT-414 in glioblastoma 
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patients are required. Bispecific T cell engagers (BiTEs) are recombinant proteins composed 
of two linked single chain variable fragments, one specifically recognizing a molecule 
expressed on T cells and one specifically recognizing a tumor antigen. Bispecific antibodies 
were active against experimental gliomas in preclinical models but clinical data are lacking so 
far (37, 38). All antibody approaches share the short half-life with the necessity of repetitive 
applications. Furthermore, the activity of antibodies which are directed against brain tumor-
expressed antigens may be limited due to their insufficient blood-brain barrier penetration.   
 
Immunovirotherapy 
This therapeutic approach is based on non-pathogenic virus strains that specifically infect 
tumor cells and damage them either directly or by delivery of therapeutic/immune 
modulatory genes such as IL-12 (39).  Currently, several phase I clinical trials in newly 
diagnosed (NCT01811992) and recurrent (NCT02026271) glioblastoma are ongoing.  The 
challenge with virus-based immunotherapies is that viruses may be cleared by the host 
immune system before exerting an effect.  
 
Inhibitors of immunosuppressive metabolic pathways 
Tryptophan depletion and kynurenine metabolites that are generated by tryptophan 2,3-
dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO) inhibit effector T cells and 
enhance the function of regulatory T cells. IDO is expressed by glioma cells. The preclinical 
assessment of IDO inhibitors demonstrated a survival benefit in an immuno-competent 
mouse glioblastoma model and a synergistic effect when applied together with 
chemoradiotherapy (40). Furthermore, a phase I clinical trial has been conducted, applying 
the IDO inhibitor indoximod in combination with temozolomide in patients with recurrent 
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glioblastoma to define the maximal tolerated dose (MTD) of the drug (41). A subsequent 
phase II study is planned. In addition, novel dual TDO and IDO inhibitors for tumor 
immunotherapy are under development. Another major immunosuppressive molecule that 
maintains the malignant phenotype of glioblastoma is transforming growth factor (TGF)-β.  
Although systemic TGF-β inhibition was associated with significant cardiac toxicity in rats 
(42), a recent phase I study demonstrated that LY2157299, a pharmacological inhibitor 
which interferes with TGF-β signaling, was safe in patients with advanced malignancies 
including gliomas (43). Clinical trials assessing this approach in more detail are ongoing.  
 
Conclusion 
Immunotherapy is one of the most active research fields in neurooncology. The key features 
of glioblastoma, that are, its immunosuppressive phenotype and the localization in an 
immune-privileged organ such as the brain with the presence of the blood brain barrier add 
another layer of complexity to the challenges of the currently explored immunotherapeutic 
approaches. So far, there are no broadly accepted criteria that can be applied for the 
selection of patients who may be ideal candidates for immunotherapy. Patients with low 
tumor burden which allows higher effector to target ratios and patients with newly 
diagnosed tumors with good performance status without prior myelosuppressive treatment 
that may impair the immune system are considered the best candidates to benefit from 
immunotherapy. However, further research is required to develop predictive markers for 
appropriate patient selection.  
Another goal that would strengthen many immunotherapeutic strategies is the identification 
of suitable target molecules. Ideally, such molecular targets are expressed in a tumor-
specific manner which minimizes the risk for off-target side effects. The combination of 
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genomic and proteomic large-scale screenings as well as functional assessments will help to 
identify suitable candidates.  
Another focus of research must aim at better understanding the side effects which occur in 
the context of immunotherapy against glioblastoma as well as the subsequent development 
of strategies to prevent or manage these immune-related adverse events. Due to the feature 
of immunological memory, immune-related adverse events can manifest even after the 
cessation of treatment and the need for a close monitoring of all patients should be 
emphasized.  Another challenge is the differentiation of radiological pseudoprogression due 
to inflammation from true tumor progression. To tackle this problem, advanced imaging 
techniques or novel biomarker might be helpful for treatment guidance and to prevent 
premature withdrawal of patients from immunotherapeutic treatments. Since 
immunological effects following immunotherapy may occur only with a delay, appropriate 
endpoints must be defined for clinical trials. Accordingly, not PFS but rather OS might be the 
most adequate endpoint to determine the anti-tumor activity of these novel drugs. 
Finally, the complexity of the immune system with its innate and adaptive arms on a cellular 
level, cytokines and antibodies as secretory molecules as well as stimulating and inhibitory 
receptors on a molecular level allow for synergistic multimodal immunotherapeutic 
strategies. These may add a strong therapeutic weapon to the conventional treatment 
options such as surgery, radiotherapy and chemotherapy, hopefully pushing some 
boundaries of glioblastoma research and ultimately improving prognosis and quality of life of 
the affected patients. 
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Key points 
 
• The emerging principles of immunotherapy against glioblastoma can be categorized 
by their dependence on the host immune system and their antigen specificity. 
Promising approaches comprise peptide and DC-based vaccination, adoptive cell 
therapy, checkpoint inhibition, tumor-targeting antibodies, immunovirotherapy and 
inhibitors of immunosuppressive metabolic molecules (Fig. 1) 
• For appropriate patient selection and treatment guidance, predictive and prognostic 
markers are needed. Furthermore, advanced imaging techniques that allow a 
differentiation of immune-related pseudoprogression due to inflammation from true 
tumor progression would be highly appreciated 
• Challenges of clinical trials exploring immunotherapeutic strategies against 
glioblastoma are delayed curve separation due to deferred anti-tumor effects and 
the reasonable design of appropriate trials that allow for a development of 
synergistic multimodal immunotherapeutic approaches 
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Figures “original” 
 
Fig. 1: Immunotherapeutic approaches against glioblastoma. Illustration of emerging 
principles of immunotherapy against glioblastoma. The different categories are underlined, 
separated by squares and comprise peptide and DC-based vaccination, adoptive cell therapy, 
checkpoint inhibition, tumor-targeting antibodies, immunovirotherapy and inhibitors of 
immunosuppressive metabolic molecules. Detailed mechanisms and abbreviations are 
explained in the text. 
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